Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05).
Sponsor: AstraZeneca
Summary
The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with asthma. Roflumilast will be administered orally once daily. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
Official title: A Confirmatory Study of APTA-2217 in Adult Patients With Bronchial Asthma (A Placebo-controlled Double-blind Comparative Study)
Key Details
Gender
All
Age Range
20 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
450
Start Date
2004-05-01
Completion Date
2007-06-01
Last Updated
2026-06-10
Healthy Volunteers
Not specified
Conditions
Interventions
Roflumilast
Locations (1)
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation
Osaka, Japan